Company News
 AES Clean Technology expands senior leadership team with key appointment
                                                    AES Clean Technology expands senior leadership team with key appointment
                                                    A leading provider of high-performance cleanroom facilities, AES Clean Technology, has appointed Brian Weed as Chief Revenue Officer (CRO)
AES Clean Technology expands senior leadership team with key appointment
                                                    AES Clean Technology expands senior leadership team with key appointment
                                                    A leading provider of high-performance cleanroom facilities, AES Clean Technology, has appointed Brian Weed as Chief Revenue Officer (CRO)
                                                
                                                                                                                                                                                                                                                                                
                                         SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
                                                    SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
                                                    The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe
SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
                                                    SGD Pharma announces the appointment of Fabio Invernizzi, General Manager West Business Unit
                                                    The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe
                                                
                                                                                                                                                                                                                                                                                
                                         Nuclera announces the appointment of Jonathan Milner as Chairman of the Board
                                                    Nuclera announces the appointment of Jonathan Milner as Chairman of the Board
                                                    Nuclera, the pioneer in bringing rapid protein prototyping to the benchtop, is delighted to announce the appointment of Jonathan Milner as the Non-executive Chairman of the...
Nuclera announces the appointment of Jonathan Milner as Chairman of the Board
                                                    Nuclera announces the appointment of Jonathan Milner as Chairman of the Board
                                                    Nuclera, the pioneer in bringing rapid protein prototyping to the benchtop, is delighted to announce the appointment of Jonathan Milner as the Non-executive Chairman of the...
                                                
                                                                                                                                                                                                                                                                                
                                         Corteria Pharmaceuticals appoints Mark Pruzanski as Chair of its Board of Directors
                                                    Corteria Pharmaceuticals appoints Mark Pruzanski as Chair of its Board of Directors
                                                    Corteria Pharmaceuticals, a biopharmaceutical company specialised in the development of transformative therapies for heart failure and obesity, announces the appointment of...
Corteria Pharmaceuticals appoints Mark Pruzanski as Chair of its Board of Directors
                                                    Corteria Pharmaceuticals appoints Mark Pruzanski as Chair of its Board of Directors
                                                    Corteria Pharmaceuticals, a biopharmaceutical company specialised in the development of transformative therapies for heart failure and obesity, announces the appointment of...
                                                
                                                                                                                                                                                                                                                                                
                                         X‑Chem transitions executives into new roles, appoints new Chief Executive Officer
                                                    X‑Chem transitions executives into new roles, appoints new Chief Executive Officer
                                                    X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced executive management team changes aimed at expanding its position as a...
X‑Chem transitions executives into new roles, appoints new Chief Executive Officer
                                                    X‑Chem transitions executives into new roles, appoints new Chief Executive Officer
                                                    X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced executive management team changes aimed at expanding its position as a...
                                                
                                                                                                                                                                                                                                                                                
                                         2cureX announces changes to the Board of Directors
                                                    2cureX announces changes to the Board of Directors
                                                    2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance resulting in four Board members...
2cureX announces changes to the Board of Directors
                                                    2cureX announces changes to the Board of Directors
                                                    2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance resulting in four Board members...
                                                
                                                                                                                                                                                                                                                                                
                                         Stuart Quin joins GHO Capital as Partner
                                                    Stuart Quin joins GHO Capital as Partner
                                                    Former CEO of Medica Group and regional CEO of Synlab to support the continued growth of GHO Capital’s portfolio and origination of future investments
Stuart Quin joins GHO Capital as Partner
                                                    Stuart Quin joins GHO Capital as Partner
                                                    Former CEO of Medica Group and regional CEO of Synlab to support the continued growth of GHO Capital’s portfolio and origination of future investments
                                                
                                                                                                                                                                                                                                                                                
                                         SpliceBio appoints leading ophthalmology expert Aniz Girach as Chief Medical Officer
                                                    SpliceBio appoints leading ophthalmology expert Aniz Girach as Chief Medical Officer
                                                    Appointment further strengthens SpliceBio’s leadership team as it accelerates lead programme targeting Stargardt disease towards clinical development
SpliceBio appoints leading ophthalmology expert Aniz Girach as Chief Medical Officer
                                                    SpliceBio appoints leading ophthalmology expert Aniz Girach as Chief Medical Officer
                                                    Appointment further strengthens SpliceBio’s leadership team as it accelerates lead programme targeting Stargardt disease towards clinical development
                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                         Sphere Fluidics appoints Dr Graeme Daniels as Vice President of Sales and Marketing
                                                    Sphere Fluidics appoints Dr Graeme Daniels as Vice President of Sales and Marketing
                                                    Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions
Sphere Fluidics appoints Dr Graeme Daniels as Vice President of Sales and Marketing
                                                    Sphere Fluidics appoints Dr Graeme Daniels as Vice President of Sales and Marketing
                                                    Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions
                                                
                                                                                                                                                                                                                                                                                
                                         Lucas Sauer-Jones appointed as Vice President & General Manager of Veranova’s New England sites
                                                    Lucas Sauer-Jones appointed as Vice President & General Manager of Veranova’s New England sites
                                                    Sauer-Jones will be responsible for US API maker Veranova’s sites in Devens and North Andover
Lucas Sauer-Jones appointed as Vice President & General Manager of Veranova’s New England sites
                                                    Lucas Sauer-Jones appointed as Vice President & General Manager of Veranova’s New England sites
                                                    Sauer-Jones will be responsible for US API maker Veranova’s sites in Devens and North Andover
                                                
                                                                                                                                                                                                                                                                                
                                         Industry veteran Abbas Hussain appointed as Chair of Asceneuron
                                                    Industry veteran Abbas Hussain appointed as Chair of Asceneuron
                                                    This follows the appointment of Barbara Angehrn Pavik as Chief Executive Officer, signaling a concerted effort to propel the development of groundbreaking treatments aimed at...
                                                
                                                                                                                                                                                                                                                                                
                                        OM Pharma appoints Roch Ogier as Chief Executive Officer
                                                    OM Pharma appoints Roch Ogier as Chief Executive Officer
                                                    OM Pharma, a global biopharmaceutical company headquartered in Switzerland, announced the appointment of Roch Ogier as Chief Executive Officer (CEO), effective January 1, 2024
Industry veteran Abbas Hussain appointed as Chair of Asceneuron
                                                    Industry veteran Abbas Hussain appointed as Chair of Asceneuron
                                                    This follows the appointment of Barbara Angehrn Pavik as Chief Executive Officer, signaling a concerted effort to propel the development of groundbreaking treatments aimed at...
                                                
                                                                                                                                                                                                                                                                                
                                        OM Pharma appoints Roch Ogier as Chief Executive Officer
                                                    OM Pharma appoints Roch Ogier as Chief Executive Officer
                                                    OM Pharma, a global biopharmaceutical company headquartered in Switzerland, announced the appointment of Roch Ogier as Chief Executive Officer (CEO), effective January 1, 2024
                                                
                                                                                                                                                                                                                                                                                
                                         Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board
                                                    Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board
                                                    The appointment supports ambitious commercialisation strategy for DNA synthesis platform, gSynth, and follows $10m Series A financing to scale operations
Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board
                                                    Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board
                                                    The appointment supports ambitious commercialisation strategy for DNA synthesis platform, gSynth, and follows $10m Series A financing to scale operations
                                                
                                                                                                                                                                                                                                                                                
                                         Astraveus appoints Dr Lars Henrik Peeck as Chief Business Development Officer
                                                    Astraveus appoints Dr Lars Henrik Peeck as Chief Business Development Officer
                                                    Appointment signifies a pivotal move for Astraveus as it expands its executive team to advance its groundbreaking cell and gene therapy (CGT) manufacturing solutions
Astraveus appoints Dr Lars Henrik Peeck as Chief Business Development Officer
                                                    Astraveus appoints Dr Lars Henrik Peeck as Chief Business Development Officer
                                                    Appointment signifies a pivotal move for Astraveus as it expands its executive team to advance its groundbreaking cell and gene therapy (CGT) manufacturing solutions
                                                
                                                                                                                                                                                                                                                                                
                                         Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
                                                    Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
                                                    Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs),...
                                                
                                                                                                                                                                                                                                                                                
                                        Santhera appoints Executive Committee members as it transitions into commercial stage
                                                    Santhera appoints Executive Committee members as it transitions into commercial stage
                                                    Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer...
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
                                                    Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
                                                    Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs),...
                                                
                                                                                                                                                                                                                                                                                
                                        Santhera appoints Executive Committee members as it transitions into commercial stage
                                                    Santhera appoints Executive Committee members as it transitions into commercial stage
                                                    Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer...
                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                         Jose Ibietatorremendia to join Veranova as SVP, General Counsel and Secretary
                                                    Jose Ibietatorremendia to join Veranova as SVP, General Counsel and Secretary
                                                    Veranova announces the appointment of Jose Ibietatorremendia as the company’s SVP, General Counsel and Secretary, reporting to Chief Executive Officer, Mike Riley
Jose Ibietatorremendia to join Veranova as SVP, General Counsel and Secretary
                                                    Jose Ibietatorremendia to join Veranova as SVP, General Counsel and Secretary
                                                    Veranova announces the appointment of Jose Ibietatorremendia as the company’s SVP, General Counsel and Secretary, reporting to Chief Executive Officer, Mike Riley
                                                
                                                                                                                                                                                                                                                                                
                                         Transgene strengthens its leadership team to accelerate its growth strategy
                                                    Transgene strengthens its leadership team to accelerate its growth strategy
                                                    Transgene is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective 1 January 2024
Transgene strengthens its leadership team to accelerate its growth strategy
                                                    Transgene strengthens its leadership team to accelerate its growth strategy
                                                    Transgene is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective 1 January 2024
                                                
                                                                                                                                                                                                                                                                                
                                         Dr Steven Chatfield, an advisor to the vaccines task force during the COVID pandemic, joins Stablepharma
                                                    Dr Steven Chatfield, an advisor to the vaccines task force during the COVID pandemic, joins Stablepharma
                                                    Stablepharma is delighted to announce that Dr Steven Chatfield, an internationally recognised expert in the field of vaccines and infectious disease, has joined the advisory board
Dr Steven Chatfield, an advisor to the vaccines task force during the COVID pandemic, joins Stablepharma
                                                    Dr Steven Chatfield, an advisor to the vaccines task force during the COVID pandemic, joins Stablepharma
                                                    Stablepharma is delighted to announce that Dr Steven Chatfield, an internationally recognised expert in the field of vaccines and infectious disease, has joined the advisory board
                                                
                                                                                                                                                                                                                                                                                
                                         Versameb names Dr Alexandre LeBeaut as Chair of the Board of Directors
                                                    Versameb names Dr Alexandre LeBeaut as Chair of the Board of Directors
                                                    Versameb AG, a preclinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, announces that its Board of Directors has unanimously appointed...
Versameb names Dr Alexandre LeBeaut as Chair of the Board of Directors
                                                    Versameb names Dr Alexandre LeBeaut as Chair of the Board of Directors
                                                    Versameb AG, a preclinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, announces that its Board of Directors has unanimously appointed...
                                                
                                                                                                                                                                                                                                                                                
                                         Kling Bio appointment of Dr Stefano Gullà as Chief Scientific Officer
                                                    Kling Bio appointment of Dr Stefano Gullà as Chief Scientific Officer
                                                    Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies
Kling Bio appointment of Dr Stefano Gullà as Chief Scientific Officer
                                                    Kling Bio appointment of Dr Stefano Gullà as Chief Scientific Officer
                                                    Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies
                                                
                                                                                                                                                                                                                                                                                
                                         Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
                                                    Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
                                                    Rentschler Biopharma announces that Dr Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective 1 December 2023
Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
                                                    Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
                                                    Rentschler Biopharma announces that Dr Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective 1 December 2023
                                                
                                                                                                                                                                                                                                                                                
                                         Zenas BioPharma strengthens executive leadership team
                                                    Zenas BioPharma strengthens executive leadership team
                                                    Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications
Zenas BioPharma strengthens executive leadership team
                                                    Zenas BioPharma strengthens executive leadership team
                                                    Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications
                                                
                                                                                                                                                                                                                                                                                
                                         Poolbeg Pharma PLC announces directorate change
                                                    Poolbeg Pharma PLC announces directorate change
Poolbeg Pharma PLC announces directorate change
                                                    Poolbeg Pharma PLC announces directorate change